Background Current guidelines recommend vitamin K antagonists (VKAs) or non-vitamin K
antagonist oral anticoagulants (NOACs) for stroke prevention in patients with non-valvular …

Purpose: To systematically review available evidence of indirect comparisons from RCTs
and direct comparisons from observational studies regarding the comparative effectiveness …

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated
with substantial increases in the risk for stroke and systemic thromboembolism. With the …

Introduction Hypertension is associated with increased risk of stroke and bleeding in
patients with atrial fibrillation (AF). In the present study, we aimed to investigate the influence …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …

Background: Several studies have investigated the role of off-label non-vitamin K antagonist
oral anticoagulants (NOACs) in patients with atrial fibrillation (AF). We aimed to compare the …

The incidence of intracranial bleeding is known to be markedly higher in Japan and other
East Asian countries than in countries outside of East Asia. Non-vitamin K antagonist oral …

Background—Novel oral anticoagulants (NOACs) have been proposed as alternatives to
vitamin K antagonists for the prevention of stroke and systemic embolism in patients with …

Objective Non-vitamin K antagonist oral anticoagulants (NOACs) are efficacious and safe
antithrombotic drugs but the non-availability of an antidote for potential fatal haemorrhagic …

Background Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) are widely used
as stroke prophylaxis in non-valvular atrial fibrillation (AF), but comparative data are sparse …